Phase II Study of GW786034 in Patients With Malignant Pleural Mesothelioma
This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
NCT00459862 — Recurrent Malignant Mesothelioma
Status: Completed
http://inclinicaltrials.com/recurrent-malignant-mesothelioma/NCT00459862/
Phase II Study of Bortezomib (VELCADE) With Cisplatin as First Line Treatment of Malignant Mesothelioma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with cisplatin may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving bortezomib together with cisplatin works as first-line therapy in treating patients with malignant mesothelioma.
NCT00458913 — Malignant Mesothelioma
Status: Completed
http://inclinicaltrials.com/malignant-mesothelioma/NCT00458913/
Phase II Study of the Combination of Bevacizumab Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Malignant Pleural Mesothelioma
The primary objective is to assess antitumor activity of the combination of bevacizumab, pemetrexed and carboplatin, in terms of time to progression.
NCT00407459 — Mesothelioma
Status: Completed
http://inclinicaltrials.com/mesothelioma/NCT00407459/
Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma
Primary Objective: - To determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignant mesothelioma. Secondary Objectives: - To explore the biologic effects of cisplatin, imatinib mesylate, and pemetrexed on tumor tissue by: - histologic analysis of biopsy tissue - by non-invasive assessments of tumor vascularity performed before, during and after treatment - electron microscopy analysis of endothelial cell architecture after patient treatment with imatinib mesylate - To explore the effects of cisplatin, imatinib mesylate, and pemetrexed on surrogate markers in serum. - To assess the rate of response to therapy. - To determine the doses of the combination regimen of cisplatin, imatinib mesylate, and pemetrexed that enables de-phosphorylation of platelet derived growth factor receptor (PDGF-R) on malignant mesothelioma tumor cells. - To determine the pharmacokinetic interaction between agents in this combination regimen.
NCT00402766 — Mesothelioma
Status: Completed
http://inclinicaltrials.com/mesothelioma/NCT00402766/
A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients With Advanced Malignant Pleural Mesothelioma
This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth.
NCT00392444 — Recurrent Malignant Mesothelioma
Status: Completed
http://inclinicaltrials.com/recurrent-malignant-mesothelioma/NCT00392444/
Safety Confirmation Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
To investigate safety of pemetrexed combined with cisplatin for chemo therapy-naive patients with malignant pleural mesothelioma
NCT00386815 — Malignant Pleural Mesothelioma
Status: Completed
http://inclinicaltrials.com/malignant-pleural-mesothelioma/NCT00386815/
Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy, such as methotrexate, vinorelbine, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Radiation therapy uses high-energy x-rays to kill tumor cells. Cisplatin may also make tumor cells more sensitive to radiation therapy. Giving chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well giving combination chemotherapy with or without surgery and chemoradiotherapy works in treating patients with malignant pleural mesothelioma.
NCT00354393 — Malignant Mesothelioma
Status: Completed
http://inclinicaltrials.com/malignant-mesothelioma/NCT00354393/
A Phase 2 Study of ALIMTA in Solid Tumor Patients With Stable Third-Space Fluid
This study will test the effects of pemetrexed on mesothelioma and non-small cell lung cancer patients with fluid around their lungs or abdomen.
NCT00316225 — Non-small Cell Lung Cancer
Status: Completed
http://inclinicaltrials.com/non-small-cell-lung-cancer/NCT00316225/
Phase II Study of AZD2171 (NSC#732208) in Patients With Malignant Mesothelioma
This phase II trial is studying how well cediranib maleate works in treating patients with malignant mesothelioma that cannot be removed by surgery. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor
NCT00309946 — Recurrent Malignant Mesothelioma
Status: Completed
http://inclinicaltrials.com/recurrent-malignant-mesothelioma/NCT00309946/
A Phase II Trial of Cisplatin, Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma
To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab
NCT00295503 — Mesothelioma
Status: Completed
http://inclinicaltrials.com/mesothelioma/NCT00295503/